National Institute of Allergy and Infectious Diseases (NIAID): all 2,445 studies

Page 15 of 25. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• Phase I Study of Vaccination Schedule of Experimental HIV VaccinesCompletedNCT00321061Phase 1
• Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 AdjuvantCompletedNCT00320658Phase 1
• Treatment of Ragweed-Allergic Asthma With an Immunostimulatory DrugTerminatedNCT00318747Phase 2
• A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of TuberculosisCompletedNCT00317330Phase 3
• Fetal Immunity to Falciparum MalariaCompletedNCT00314899
• Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai ChildrenCompletedNCT00312091Phase 1/2
• Cell-Mediated Immune Responses to Influenza A/H5N1 VaccineCompletedNCT00311727Not applicable
• Chart Review of Antivirals for Influenza in InfantsCompletedNCT00311701
• Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 StudiesCompletedNCT00311688
• St. Jude Open Label H5 TrialCompletedNCT00311675Phase 1/2
• Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing FacilitiesCompletedNCT00311649Phase 1/2
• H5N1 Vaccine Intramuscular Versus Intradermal in Healthy AdultsCompletedNCT00310206Phase 1
• Noninvasive Methods to Monitor Graft Survival in Kidney Transplant PatientsCompletedNCT00308802
• Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy InfantsCompletedNCT00308412Phase 1
• Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell LymphomaCompletedNCT00307177Phase 2
• Rheumatic Heart Disease Prevalence in Leon, NicaraguaCompletedNCT00307112
• Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICUTerminatedNCT00307099Phase 3
• Molecular Epidemiology of Streptococcus Pyogenes Among Children in Bamako, MaliCompletedNCT00305123
• SIGA-246 to Treat SmallpoxWithdrawnNCT00303225Phase 1
• CMV Infection in Adolescent MalesTerminatedNCT00302029
• Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy AdultsCompletedNCT00301184Phase 1
• Phase I Study of West Nile Virus VaccineCompletedNCT00300417Phase 1
• SP Resistance and Falciparum Malaria TransmissionWithdrawnNCT00299247Phase 3
• Azithromycin Combination Therapy for MalariaCompletedNCT00299208Phase 2
• Safety and Dose Study of Peramivir for Influenza TreatmentCompletedNCT00297050Phase 1
• Acute HIV Infection Observational StudyCompletedNCT00296660
• H5 Vaccine Alone or With Adjuvant in Healthy AdultsCompletedNCT00296634Phase 1/2
• PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for MalariaCompletedNCT00295581Phase 1
• H5 Vaccine Alone or With Aluminum Hydroxide in Elderly AdultsCompletedNCT00294099Phase 1/2
• Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis PatientsCompletedNCT00290823Phase 3
• Rift Valley Fever in KenyaCompletedNCT00287014
• Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral TherapyCompletedNCT00286767
• Incidence of Group A Strep Pharyngitis in School Children in FijiCompletedNCT00284882
• Prevalence of RHD, Pyoderma and Scabies in Children in FijiCompletedNCT00284843
• H5 Adult - Chiron Study of Bird Flu VaccineCompletedNCT00280033Phase 1/2
• Estimating the Incidence of HIV Infection Among Men Who Have Sex With Men in Peru and EcuadorCompletedNCT00279331
• Prevalence of HIV and Other Sexually Transmitted Infections Among Female Sex Workers and Miners in Honghe Prefecture, Yunnan Province, ChinaCompletedNCT00278499
• Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria ResearchCompletedNCT00277849
• Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected IndividualsCompletedNCT00272493Phase 2
• Bacterial Pulmonary Infection in PICUCompletedNCT00271531
• Social and Economic Outcomes of HIV/AIDS Care and Treatment in HIV Infected South African AdultsCompletedNCT00270764
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy AdultsCompletedNCT00270699Phase 1
• Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected PatientsCompletedNCT00270465Phase 1
• Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected AdultsCompletedNCT00270218Phase 1
• TY800 Dose Escalation (Typhoid)CompletedNCT00269295Phase 1/2
• Studies of Disorders in Antibody Production and Related Primary Immunodeficiency StatesTerminatedNCT00266513
• GAS Epi Study to Measure Age-Related Antibody Titers to J8 VaccineCompletedNCT00264784
• Hospital Based Incidence of Group A Streptococcal Disease in FijiCompletedNCT00264771
• STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable ImmunodeficiencyCompletedNCT00263237Phase 1
• Omalizumab to Treat Hyper-IgE (Job's) SyndromeCompletedNCT00260702Phase 1
• Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected ChildrenCompletedNCT00260078Phase 1/2
• Directly Observed Therapy for HIV Infected AdolescentsCompletedNCT00259389Not applicable
• Immune Responses to Two Dose Varivax +/- MMR-IITerminatedNCT00258726Phase 1/2
• Immune Response to Mycobacterium Tuberculosis InfectionCompletedNCT00257907
• Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV DrugsCompletedNCT00257127Not applicable
• Immunogenicity and Safety of Different Doses of Fluzone® InfluenzaCompletedNCT00253734Phase 2
• The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's DiseaseCompletedNCT00250198Phase 2
• RSV Disease in the ElderlyCompletedNCT00246480
• H5 Booster After a Two Dose ScheduleCompletedNCT00240968Phase 2
• Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) VaccineCompletedNCT00240903Phase 1
• Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as PromisedCompletedNCT00238459
• When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)CompletedNCT00234091Phase 3
• Inactivated Influenza Vaccine in Infants 10-22 Weeks of AgeCompletedNCT00231920Phase 1
• A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and FlumistCompletedNCT00231907Phase 1
• Inactivated Influenza A/H5N1 Vaccine in the ElderlyCompletedNCT00230750Phase 1/2
• Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)WithdrawnNCT00230035Phase 2
• Long Term Follow-Up of HIV Infected Patients Who Have Previously Participated in HIV Clinical TrialsCompletedNCT00183287
• Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV InfectionCompletedNCT00183261Phase 2
• Tuberculosis Immunity in ChildrenCompletedNCT00170638
• Novel Protective UndergloveCompletedNCT00170586Phase 2
• Impact of Gender on PatientsCompletedNCT00170560
• Comparison of Delivery Routes of Flu Vaccine in AdultsCompletedNCT00170547Phase 2
• Intervention for Male STDs in IndiaTerminatedNCT00170534Not applicable
• Mol Epi GrAS in NicaraguaTerminatedNCT00170521
• Young Adult Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170508Not applicable
• Acute Viral Respiratory Infections in ElderlyTerminatedNCT00170495
• Elderly Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170482
• Trivalent rHA Dose Escalation Study in Elderly SubjectsCompletedNCT00170443Phase 2
• TB Nutrition, Immunology and EpidemiologyCompletedNCT00170404Phase 3
• Research for Elim of FilariasisCompletedNCT00145223
• Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected AdultsCompletedNCT00141024Phase 1
• Funguria in Hospitalized PatientsCompletedNCT00138502
• Papua New Guinean Duffy Negativity And Vivax MalarTerminatedNCT00138489
• New Challenge Pool of Norwalk Virus InoculumCompletedNCT00138476Phase 1
• West Nile Virus Natural HistoryCompletedNCT00138463
• Urinary Schistosomiasis InfectionCompletedNCT00138450
• Monoclonal Antibody for Treatment of Inhalation AnthraxCompletedNCT00138411Phase 1
• T-cell Response-Flu Risk in Older AdultsCompletedNCT00138398Not applicable
• Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 AmendmentCompletedNCT00138385Phase 4
• Mass Treatment T Solium Community StudyTerminatedNCT00138359Not applicable
• Epi Cystic Hydatid Disease PeruCompletedNCT00138346
• Mercury Levels in Premature and LBW Infants Receiving Thimerosal-containing VaccinesCompletedNCT00138333
• Herpevac Neonatal SubstudyTerminatedNCT00138320
• Correlates of Protection in GhanaCompletedNCT00138307
• Influenza Immunity Against Pandemic Respiratory VirusCompletedNCT00138281Phase 4
• Pilot Study Freeze and Transport Immune CellsCompletedNCT00138268
• Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella VaccinesTerminatedNCT00138255
• Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid AbusersTerminatedNCT00134875Not applicable
• Proteomic Profiling for InfluenzaCompletedNCT00133588Phase 4
• 9-valent CRM 197 PneumococcalCompletedNCT00133549Phase 2

← National Institute of Allergy and Infectious Diseases (NIAID) overview and focus areas